Form 4: Accelerate Diagnostics Director Ogilvie Receives Stock Units

Director Marran H. Ogilvie of Accelerate Diagnostics, Inc. was granted 66,667 restricted stock units (RSUs) on May 20, 2024, which vest on the first anniversary of the grant date, with deferred receipt of shares until departure from the board.

Summary

• On May 20, 2024, Marran H. Ogilvie, a director of Accelerate Diagnostics, Inc., was granted 66,667 restricted stock units (RSUs).
• The RSUs vest on the first anniversary of the grant date.
• If the reporting person leaves in good standing before the vesting date, the RSUs will vest pro-rata based on months served.
• Ogilvie has elected to defer receipt of the shares of common stock upon vesting of the RSUs until within 30 days following departure from the board of directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of RSUs is a standard practice and aligns the director's interests with shareholders. The deferred receipt of shares could be seen as a positive sign of long-term commitment.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• Deferred receipt of shares may signal a long-term commitment to the company.

Future Outlook

The director will receive shares of common stock upon vesting of the RSUs, with the actual timing dependent on the director's continued service and departure from the board.

Industry Context

Granting stock options and restricted stock units to directors is a common practice to incentivize and align their interests with the long-term performance of the company. This is a standard form 4 filing related to insider transactions.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning the director's interests with the company's long-term success.

Key Dates